ZEISS Medical Technology has received approval from China’s National Medical Products Administration (NMPA) for its latest laser vision correction system, the VISUMAX® 800 with SMILE® pro software. This next-generation femtosecond laser enables faster, more precise treatments for nearsightedness and astigmatism.
With over 10 million eyes treated globally using ZEISS SMILE and SMILE pro technology, the approval marks a significant milestone, reinforcing its growing adoption in Asia, Europe, and the U.S. The launch of the VISUMAX 800 in China aims to meet the increasing demand for advanced laser vision correction, offering ophthalmologists cutting-edge tools to improve surgical precision, efficiency, and patient experience.
Revolutionizing Laser Vision Correction in China
China has seen a surge in interest in laser vision correction, driven by rising cases of myopia. According to industry estimates, over 600 million people in China are affected by myopia, creating a strong demand for advanced refractive surgery solutions.
“With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety, and efficiency to benefit both surgeons and their patients,” said Maximilian Foerst, Head of ZEISS Greater China.
The ZEISS VISUMAX 800 with SMILE pro software is designed to meet this demand, offering faster treatment, improved workflow efficiency, and greater flexibility. The approval further strengthens ZEISS’s commitment to supporting ophthalmologists with state-of-the-art technology.
What Makes the VISUMAX 800 with SMILE Pro Software Unique?
The VISUMAX 800 represents a leap forward in laser vision correction technology. Here are some key features:
1. Faster and More Efficient Treatment
- The 2 MHz laser pulse repetition rate reduces treatment time significantly, allowing surgeons to create the lenticule in less than 10 seconds.
- A shorter procedure time minimizes stress for both the surgeon and the patient.
2. Enhanced Surgical Precision and Flexibility
- The system is designed with a smaller footprint, making it adaptable to various clinical environments.
- It is compatible with different patient beds, ensuring flexibility in surgical settings.
3. Advanced Workflow Enhancements
ZEISS has integrated several innovative features into the VISUMAX 800 to optimize surgical workflow:
- CentraLign® Centration Aid – A computer-controlled function that helps surgeons accurately center the laser.
- OcuLign® Cyclotorsion Adjustment – Helps compensate for potential cyclotorsion movements during surgery.
- VISULYZE User Nomograms – Provides data-driven insights for surgeons, helping them analyze patient information and adjust their technique accordingly.
These enhancements allow ophthalmologists to improve surgical precision, patient outcomes, and overall efficiency.
Strengthening ZEISS’s Position in the Chinese Market
The introduction of the VISUMAX 800 with SMILE pro software further solidifies ZEISS’s leadership in the Chinese ophthalmic market.
“ZEISS further sets itself apart in China with the availability of the VISUMAX 800 with SMILE pro software, providing the latest digital technology to meet the evolving needs of refractive surgeons worldwide,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology.
The technology is expected to be widely adopted in China, allowing ophthalmologists to deliver faster, safer, and more efficient vision correction for millions of patients.
Why This Approval Matters
China has one of the highest myopia rates globally, especially among young people. The approval of the ZEISS VISUMAX 800 means that more patients will have access to state-of-the-art laser vision correction, improving their quality of life.
Surgeons will also benefit from a highly efficient system that enhances workflow and reduces procedure time, allowing them to treat more patients with greater accuracy.
Stay updated with the latest medical technology news at Coleman News.
